Genetic medicine startup secures $70M to advance RNA-based obesity therapy into clinical trials
Moonwalk Biosciences has raised $70 million to support its obesity program, which uses small interfering RNA (siRNA) technology. The funding will enable the company to move the candidate into clinical testing, reflecting a strategic shift in its genetic medicine approach.
Moonwalk Biosciences has secured $70 million in new funding, earmarked specifically for its obesity-focused research. The company's approach leverages small interfering RNA (siRNA), a genetic tool designed to modulate gene expression. This capital injection will facilitate the transition of its lead candidate from preclinical work into human clinical trials. The investment also signals a notable pivot within the company's broader genetic medicine strategy, prioritizing metabolic conditions.
This funding round could accelerate the development of a novel obesity treatment, potentially offering an alternative to current injectable therapies. If successful, siRNA-based approaches may provide longer-lasting effects by targeting genetic drivers of weight gain, which could benefit patients seeking durable metabolic management. However, the therapy remains in early stages, so its societal impact will depend on future trial outcomes, regulatory approvals, and accessibility.